Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
15.5
27.59
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one KNSA stock under the Base Case scenario is 29.03 USD. Compared to the current market price of 22.22 USD, Kiniksa Pharmaceuticals Ltd is Undervalued by 23%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Kiniksa Pharmaceuticals Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for KNSA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Kiniksa Pharmaceuticals Ltd
Balance Sheet Decomposition
Kiniksa Pharmaceuticals Ltd
Current Assets | 301m |
Cash & Short-Term Investments | 218.8m |
Receivables | 20.5m |
Other Current Assets | 61.8m |
Non-Current Assets | 241.4m |
PP&E | 12.4m |
Intangibles | 16.8m |
Other Non-Current Assets | 212.3m |
Current Liabilities | 84.3m |
Accounts Payable | 7.4m |
Accrued Liabilities | 65.4m |
Other Current Liabilities | 11.5m |
Non-Current Liabilities | 23m |
Other Non-Current Liabilities | 23m |
Earnings Waterfall
Kiniksa Pharmaceuticals Ltd
Revenue
|
384.1m
USD
|
Cost of Revenue
|
-52.6m
USD
|
Gross Profit
|
331.5m
USD
|
Operating Expenses
|
-357.7m
USD
|
Operating Income
|
-26.2m
USD
|
Other Expenses
|
17.2m
USD
|
Net Income
|
-9.1m
USD
|
Free Cash Flow Analysis
Kiniksa Pharmaceuticals Ltd
USD | |
Free Cash Flow | USD |
KNSA Profitability Score
Profitability Due Diligence
Kiniksa Pharmaceuticals Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Kiniksa Pharmaceuticals Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
KNSA Solvency Score
Solvency Due Diligence
Kiniksa Pharmaceuticals Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Score
Kiniksa Pharmaceuticals Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KNSA Price Targets Summary
Kiniksa Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for KNSA is 34.88 USD with a low forecast of 30.3 USD and a high forecast of 42 USD.
Dividends
Current shareholder yield for KNSA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
KNSA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The firm is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company’s programs include Rilonacept, which is a protein for inhibiting interleukin-1 alpha and interleukin-1beta; Mavrilimumab, is a monoclonal antibody that antagonizes the signaling of granulocyte macrophage colony stimulating factor, or GM-CSF; KPL-716, is a monoclonal antibody that simultaneously inhibits the signaling of the cytokines interleukin-31, or IL-31, and oncostatin M, or OSM, by targeting their common receptor subunit, oncostatin M receptor beta, or OSMR beta; KPL-045 is a monoclonal antibody inhibitor of the CD30/CD30L interaction, a T-cell co-stimulatory receptor involved in activated T-memory cell function, and KPL-404, is a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity.
Contact
IPO
Employees
Officers
The intrinsic value of one KNSA stock under the Base Case scenario is 29.03 USD.
Compared to the current market price of 22.22 USD, Kiniksa Pharmaceuticals Ltd is Undervalued by 23%.